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Background/aim: A proliferation-inducing ligand (APRIL) has been investigated as a prognostic marker in chronic lymphocytic
leukemia (CLL) patients. However, there is no cut-off level for serum APRIL (sAPRIL) levels that predict time to treatment in CLL
patients.
Materials and methods: Between May and December 2012, 94 consecutive CLL patients and 25 healthy controls were assessed. sAPRIL
levels were measured by ELISA. Demographic data and prognostic markers were obtained from the patients’ files. Treatment-naïve
patients were followed up for 6.5 years for any treatment need.
Results: Patients were divided into 3 groups: Treatment-naïve (n = 47), chemotherapy receiving (n = 25), and those who had received
chemotherapy previously (n = 22). There was no difference in median sAPRIL levels of patients who were receiving chemotherapy at
the sampling time and the healthy controls, which indicates that sAPRIL levels might be influenced by treatment. For treatment-naïve
patients, the best cut-off in predicting time to treatment was found at the sAPRIL level of 2.04 ng/mL, with 78% sensitivity and 63%
specificity. Time to treatment was significantly earlier in the APRIL high group (n = 27) than in the APRIL low group (n = 20) (P =
0.010, log-rank test).
Conclusion: sAPRIL, a simple, promising blood test which can be measured by ELISA, will likely obtain a place in the wide range of
prognostic markers in CLL. Prospective large-scale studies are required to validate and confirm the feasibility of the proposed cut-off
level of 2.04 ng/mL as a predictor of time to treatment in treatment-naïve CLL patients.
Key words: Chronic lymphocytic leukemia, treatment, survival, prognosis, chemotherapy

1. Introduction
Chronic lymphocytic leukemia (CLL) is a progressive
malignant disease characterized by the accumulation
of monoclonal lymphocytes in peripheral blood, bone
marrow, and lymphoid tissues. Immunophenotypic analysis
by flow cytometry reveals CD5, CD19, CD20, and CD23
expression in B cells [1]. Treatment is required in cases with
active disease, which is defined by the following conditions:
B symptoms, progressive splenomegaly, hepatomegaly,
lymphadenopathy or lymphocytosis, evidence of bone
marrow failure that is not caused by autoimmune phenomena
and organomegaly, and autoimmune phenomena refractory
to conventional therapy [2]. Unlike other types of leukemia,
treatment is usually deferred until advanced stages of
disease [2]. There are no treatment options for cure except
for allogeneic bone marrow transplantation.

There are 2 clinical staging systems in CLL: the Rai
[3] and the Binet systems [4]. Although they are easy to
use and are widely used for determining prognosis, both
staging systems fall short in identifying a proportion
of CLL patients who have early-stage disease but are
at high risk for faster progression. Therefore, there has
been a considerable amount of research to identify
patients at risk of progression [5]. Several complementary
parameters have been suggested to improve the prediction
potential of prognostic scoring systems, such as shortened
lymphocyte doubling time (LDT), beta2-microglobulin
(β2M), lactate dehydrogenase (LDH), thymidine kinase,
CD49d levels, CD38, and zeta-chain–associated protein
kinase 70 (ZAP70) expression. Furthermore, cytogenetic
abnormalities including deletions in chromosomes 11,
13, and 17, mutations in the immunoglobulin heavy
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chain gene variable region (IGHV) and TP53 and several
mutated genes that are involved in DNA damage, Notch
signaling, inflammatory pathways, and cytokine signaling
have been identified as prognostic markers [5,6]. Since
none of the aforementioned parameters can identify all
patients at high risk and the routine clinical use of most of
them is limited, there is an unmet need for a better marker
for prognosis.
A proliferation-inducing ligand (APRIL) belongs to
the family of tumor necrosis factor ligands and has been
known to be associated with B cell proliferation and
survival [7]. It plays different roles at various stages of
B-cell ontogeny. There have been some observations that
APRIL might play a role in the pathogenesis of CLL. First,
CLL cells have been shown to express APRIL, which was
held responsible for the resistance to apoptosis of CLL
cells [7]. Second, nurse-like cells that are a part of the CLL
microenvironment have been shown to express APRIL
[8]. In addition to those, APRIL transgenic mice are
prone to develop B-cell–associated lymphoid tumors [9].
Moreover, serum APRIL (sAPRIL) levels have been found
to be associated with a shorter treatment-free interval in
newly diagnosed CLL patients [10,11]. However, there are
conflicting data regarding its prognostic role in survival
[10,12,13]. Finally, there is no data on whether sAPRIL
levels are still a useful prognostic tool during the course
of the disease, and how they vary according to treatment.
The aim of the present study was (1) to compare
sAPRIL levels of CLL patients with those of age- and
sex-matched healthy subjects, (2) to investigate the
relationship between sAPRIL levels and other common
prognostic factors, (3) to find out whether sAPRIL levels
are influenced by treatment, (4) to determine whether
sAPRIL levels can predict time to treatment in the setting
of a prospective observational study over a time span of up
to 6.5 years, and (5) to identify a cut-off level for prediction
of time to treatment.
2. Materials and methods
Between May and December 2012, venous blood samples
were drawn from 104 consecutive CLL patients and 25
age- and sex-matched healthy controls. Treatment-naïve
patients have been followed up with for 6.5 years for any
treatment requirements and survival. CLL was diagnosed
according to the National Cancer Institute Working Group
criteria [14]. The study was supported by an unrestricted
grant by Scientific Research Projects Coordination Unit of
İstanbul University (Project No.: 19694) and was approved
by the Ethics Committee of the Cerrahpaşa Medical
Faculty (43458/2011). Written informed consent was
obtained from all of the patients and healthy controls. This
study was conducted in accordance with the 1964 Helsinki
Declaration and its later amendments or comparable
ethical standards.

Data at initial presentation of the patients were
reviewed from the medical records for the following
parameters: demographic features, the presence of
organomegaly and peripheral lymphadenopathy, complete
blood count, LDH and β2M levels, ZAP-70 positivity,
the percentage of CD38+ cells in the flow cytometry, and
time to treatment. The cut-off levels for CD38+ positivity
and β2M were 30% and 2 mg/L, respectively. The cut-off
of del17p performed by fluorescent in situ hybridization
(FISH) in our laboratory was 10%.
Venous blood samples were collected in anticoagulantfree tubes without venous stasis after 12 h of overnight
fasting, and centrifuged immediately (3000 g) for 10 min
at +4 °C. The serum was stored at –80 °C until the time of
assay. sAPRIL levels were measured in duplicate aliquots,
using a human enzyme-linked immunosorbent assay
(ELISA) test according to the manufacturer’s instructions
(Bender MedSystems, Vienna, Austria). The coefficients
of intra- and interassay variations were 4.1% (n = 10) and
7.2% (n = 10), respectively.
Statistical analysis was done using SPSS 17.0.
Categorical variables were compared by chi-square test.
Continuous variables were compared with Student’s t-test
when data were parametric and with the Mann–Whitney U
test when data were nonparametric. Spearman’s correlation
test was used to assess the correlation between measures.
Summary receiver operating characteristic (ROC) curve
and log-rank test were used to calculate whether sAPRIL
levels predicted time to treatment in treatment-naïve CLL
patients. Statistical significance was considered at the twotailed 0.05 level.
3. Results
Of 104 patients, 10 were excluded from the study
due to hemolyzed blood samples (3 patients), Richter
transformation at the time of recruitment (3 patients),
and inadequacy of medical records (4 patients). Overall,
samples from 94 CLL patients and 25 healthy donors were
eligible for the final analysis.
Median sAPRIL levels of CLL patients were found to be
significantly higher than those of 25 healthy donors (2.63
ng/mL, IQR: 0.97–3.75 vs 1.29 ng/mL, IQR: 0.58–2.19,
respectively; P = 0.006) (Figure 1). At the sampling time,
47 patients were treatment-naïve, 25 patients were actively
receiving chemotherapy, and 22 patients had received
chemotherapy previously and had been treatment-free for
≥3 months. The median sAPRIL levels of 47 treatmentnaïve and 22 treated patients were significantly higher than
those of the healthy controls (2.78 ng/mL, IQR: 0.61–3.78
vs. 1.29 ng/mL, IQR: 0.58–2.19; P = 0.028 and 3.54 ng/mL,
IQR: 2.23–6.51 vs. 1.29 ng/mL, IQR: 0.58–2.19); P <0.001,
respectively). However, the median sAPRIL levels of 25
patients actively receiving chemotherapy and 25 healthy
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Figure 1. Median sAPRIL levels of healthy controls, CLL patients, treatment-naïve patients (group A),
patients receiving chemotherapy (group B), and patients who were received chemotherapy previously
(group C).

controls were not different (1.56 ng/mL, IQR: 0.84–2.99
vs. 1.29 ng/mL, IQR: 0.58/–2.19; P = 0.295) (Figure 1).
Although we did not measure sAPRIL levels prior to or
after chemotherapy in each patient, obtained data showing
no difference in median sAPRIL levels of patients who
were receiving chemotherapy and the controls made us
think that sAPRIL levels might be influenced by treatment.
We then extended the study to follow-up with treatmentnaïve patients to delineate the prognostic role of sAPRIL
in these patients.
Treatment-naïve patients (group A)
There were 47 (M/F: 30/17) treatment-naïve CLL
patients. ZAP-70 results were available in 9 patients, with
2 of them being positive.
sAPRIL levels were found to be negatively correlated
with haemoglobin levels (r = –0.298; P = 0.037) and
platelet counts (r = –0.321; P = 0.025). There were no
correlations with prognostic indicators such as age (r =
0.069; P = 0.64), Rai (r = 0.151; P = 0.31) and Binet stages
(r = 0.171; P = 0.24), lymphocyte counts (r = 0.039; P =
0.79), β2M (r = 0.121; P = 0.18), or CD38 levels (r = 0.037;
P = 0.85). The median sAPRIL levels were not different
among the patients who had high or normal LDH, CD38,
and β2M levels (data not shown). Clonal abnormality was
not evaluated due to the low number of detected cases (5
patients).
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The median follow-up times of the patients since
diagnosis and serum sampling were 114 months (IQR:
90-138) and 78 months, respectively. Among the 47
patients, 23 received chemotherapy due to progressive
disease. The median time from sampling to treatment
in these 23 patients was 37 months (IQR: 17–47). Seven
patients died during the follow-up period, and 5 of them
received treatment due to progressive CLL and died due
to refractory disease and infection after a median follow
up of 1.5 years (range: 1–3) following treatment initiation.
The remaining 2 treatment-naïve patients died due to
cardiovascular disease 3.5 and 4 years after the study entry;
at the time of death, they still had not required therapy.
The ROC curve of sAPRIL levels in predicting time to
treatment showed an area under the curve of 0.75 (Figure
2). The best cut-off in terms of prognostic effectiveness
was found at an sAPRIL level of 2.04 ng/mL, with 78%
sensitivity and 63% specificity. The patients were divided
into 2 groups according to the cut-off level: sAPRIL high
(n = 27) and sAPRIL low (n = 20). The 2 groups were
similar with respect to demographic data and prognostic
factors (Table). In the sAPRIL high group, 18 of the 27
patients received chemotherapy during follow-up whereas
only 5 of the 20 patients in the sAPRIL low group required
treatment. Time to treatment from sampling (Figure 3a)
and diagnosis (Figure 3b) was significantly earlier in the
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Figure 2. The ROC curve of sAPRIL in predicting time for the
treatment.

sAPRIL high group than in the sAPRIL low group (P =
0.010, P = 0.003, log-rank test, respectively). Among
the 5 patients who had died due to refractory CLL and
infection, 4 were in the sAPRIL high group and 1 was in
the sAPRIL low group. One patient died in each group due
to cardiovascular disease.
4. Discussion
Several studies have been conducted to predict outcomes
in patients with CLL since patients having early-stage
disease have a variable clinical course. None of the
prognostic factors mentioned above can stratify all
patients at high risk for progression. Moreover, most of
them are not available in routine clinical practice. It would
be desirable to have a simple prognostic test. sAPRIL levels
are easily measured by ELISA and have been investigated
as a prognostic marker in CLL patients. However, previous
studies have reported conflicting results with regard to
the prognostic role of sAPRIL in terms of overall survival
[12,13,10]. Additionally, its prognostic role has been
mostly studied in newly diagnosed patients. In the present
study, we included consecutive CLL patients. Although our
patient population was heterogeneous regarding disease
duration, sAPRIL levels again predicted time to treatment
in treatment-naïve CLL patients based on an ROCanalysis–defined threshold of 2.04 ng/mL. We also found
that sAPRIL levels seem to be influenced by treatment.
Tecchio and colleagues [10] reported that high sAPRIL
levels were associated with an earlier progression in

low-risk CLL patients. Ferrer and colleagues [11] also
supported this finding and showed that a combined
analysis of B-cell activating factor and sAPRIL levels may
be more useful to predict disease progression in CLL
patients. Our results confirmed those of the previous
studies, showing that sAPRIL levels can predict time to
treatment in treatment-naïve CLL patients. However,
unlike the 2 previous retrospective studies in which the
serum samples were collected at the time of diagnosis, our
study was cross-sectional and included samples obtained
at the diagnosis or during the course of the disease.
Despite this heterogeneity in the collection time points of
the samples, sAPRIL remained a useful predictor of time
to treatment in treatment-naïve CLL patients. This finding
is remarkable as it indicates that sAPRIL levels may be
used as a prognostic factor independent of time of sample
collection. Moreover, unlike in the previous studies, in our
hands, the ROC curve provided a cut-off level of 2.04 ng/
mL, which clearly differentiated patients who would need
treatment.
Serum [12] and plasma [13] APRIL levels were found
to be associated with overall survival in 2 studies, but not
in Tecchio’s study [10]. In the study by Planelles et al. [12],
the patient group with high sAPRIL levels included more
patients with advanced-stage disease when compared to
the group with low sAPRIL levels. This might be the reason
for the conflicting results with regard to the prognostic
potential of sAPRIL levels. On the other hand, the
demographic and clinical differences among the sAPRIL
high and sAPRIL low groups were not clearly represented
in Bojarska’s study [13]. In our study, we could not evaluate
the impact of sAPRIL levels on overall survival of CLL
patients because the follow-up period was relatively short;
we only lost 5 patients due to refractory disease during
the follow-up. However, 4 of these 5 patients were in the
sAPRIL high group.
sAPRIL levels were detected to be increased in our
CLL population compared to healthy controls, paralleling
the results of the previous reports. Moreover, we also
demonstrated that sAPRIL levels in patients receiving
chemotherapy were not different from those of the healthy
controls. Thus, this finding indicates that sAPRIL levels
were not useful for predicting the prognosis in patients
undergoing treatment. Chemotherapy apparently led to a
decrease in sAPRIL levels. In addition to this, we could
demonstrate a negative correlation between the sAPRIL
levels and hemoglobin as well as platelet counts. This
finding was considered to be indirect evidence for an
association between the leukemic cell burden and sAPRIL
levels.
Our study had some limitations. First of all, the
correlation of sAPRIL levels with cytogenetic abnormalities
and VH mutation could not be investigated due to the
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Table. The demographic and clinical characteristics of sAPRIL high and sAPRIL low group.
APRIL high group
(n = 27)

APRIL low group
(n = 20)

P-value

Mean ± SD age at sampling time, years

67 ± 12.4

66.9 ± 10.2

0.98

Mean ± SD age at diagnosis, years

64.3 ± 10.5

61 ± 10.2

0.48

Male, n (%)

19 (70.4)

11 (55)

0.36

A

22

16

0.89

B

3

3

0.69

C

2

1

0.74

Low-risk

18

15

0.83

Intermediate-risk

7

3

0.36

High-risk

2

2

0.75

Median (IQR) lymphocyte, mm3

23.700
(11.100-56910)

18.755
(15.112-30300)

0.83

LDH, n (%)

25 (93)

17 (85)

0.4

Median (IQR) β2M (mg/L)

2125 (1680-2862)

1985 (1759-2637)

0.21

High CD38, n/N (%)

0/13

3/17 (18)

0.11

17p deletion, n/N (%)

4/15 (26)

1/9 (11)

0.36

Patients who required chemotherapy
during the follow-up, n (%)

18 (67)

5 (25)

0.004

Binet stage

Modified Rai stage

APRIL: a proliferation-inducing ligand; β2M: beta2-microglobulin; LDH: lactate dehydrogenase.

Figure 3. Kaplan-Meier graph shows an earlier time to treatment from sampling (3a) and diagnosis (3b).
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low number of patients with sufficient cytogenetic data.
However, sAPRIL high and sAPRIL low groups were
similar with regard to other prognostic factors. Second
of all, the impact of sAPRIL levels on overall survival
could not be determined due to the inadequate followup time. Last but not least, blood sampling times were
heterogeneous—some blood samples were drawn at
diagnosis, others during the course of the disease prior
to or after a treatment episode. However, this limitation
turned out to be a strength of the study, demonstrating the
prognostic role of sAPRIL regardless of the collection time
of serum samples in treatment-naïve CLL patients. The low
number of treatment-naïve patients, the cross-sectional
design of the study, and the relatively short duration of
follow-up were other limitations.
In conclusion, sAPRIL levels are higher in CLL
patients than in healthy controls, a finding that is in line
with the current literature. However, this only holds true
for treatment-naïve or treatment-free patients, not for
those who are undergoing chemotherapy. Furthermore,
sAPRIL levels seem to be correlated with leukemic cell
burden. sAPRIL, a simple, promising blood test which can
be measured by ELISA, will seemingly attain a place in the

wide range of prognostic markers for CLL. Prospective
large-scale randomized studies are required to validate and
confirm the feasibility of the proposed cut-off level of 2.04
ng/mL as a predictor of time to treatment in treatmentnaïve CLL patients.
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